Jan Bogaerts - Concepedia

Author

Jan Bogaerts

European Organisation for Research and Treatment of Cancer ORCID

Also Known As

Bogaerts, Jan, J Bogaerts, J. Bogaerts, Jan Bogaerts, Marc van de Vijver

195

Publications

53.7K

Citations

H-Index

Concepts

All Affiliations

European Organisation for Research and Treatment of Cancer Institut Jules Bordet The Netherlands Cancer Institute Université Libre de Bruxelles Radboud University Nijmegen

About

Jan Bogaerts is an author at European Organisation for Research and Treatment of Cancer specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	41	35.2K
2	Health Sciences	18	18	30.2K
3	Engineering	2	2	637
4	Law	1	1	1.8K
5	Public Health	1	1	200

Jan Bogaerts

Publications

42.8K

Citations

H-Index

Page 1

	Year	Citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E. Eisenhauer, P. Therasse, Jan Bogaerts, European Journal of Cancer Surgical OncologyRecist GuidelineMedicineCancer ManagementSolid Tumours	2008	28.6K
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts, New England Journal of Medicine	2016	2K
RECIST 1.1—Update and clarification: From the RECIST committee Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries, European Journal of Cancer Public PolicyRecist 1.1—UpdateLawAdministrative LawPolicy Process	2016	1.8K
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial Mila Donker, Geertjan van Tienhoven, Marieke E. Straver, The Lancet Oncology Surgical OncologyBreast OncologyRadiation TherapyMedicineBreast Cancer	2014	1.8K
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer Marc Buyse, Sherene Loi, Laura van’t Veer, JNCI Journal of the National Cancer Institute	2006	1.2K
Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group Nina Bijker, Philip Meijnen, Johannes L. Peterse, Journal of Clinical Oncology	2006	657
ESMO-Magnitude of Clinical Benefit Scale version 1.1 Nathan I. Cherny, Urania Dafni, Jan Bogaerts, Annals of Oncology Clinical EffectivenessPatient SafetyClinical TrialsOutcomes ResearchPatient-reported Outcome	2017	625
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer Pierre Farmer, Hervé Bonnefoi, Pascale Anderle, Nature Medicine Breast OncologyOncologyEngineeringTumor HeterogeneityStroma-related Gene Signature	2009	615
Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial Saskia Litière, Gustavo Werutsky, Ian S. Fentiman, The Lancet Oncology Surgical OncologyBreast OncologyMedicineBreast CancerSurgery	2012	543
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age Martine Piccart, Laura van ‘t Veer, Coralie Poncet, The Lancet Oncology Breast OncologyEarly Breast CancerMedicine70-Gene SignatureClinical Trials	2021	336

Page 1